Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
By Daniel F. Martin, M. Maguire, Gui-shuang Ying, J. Grunwald, S. Fine, G. Jaffe. New England Journal of Medicine, 2011
2,654 citations recorded by the source corpus.
BACKGROUND Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a non-inferiority limit of 5 letters on the eye chart. RESULTS Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P = 0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. CONCLUSIONS At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.)
Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/b9157e6c4d79f6dd5fc89288e9e879658bfef7c3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Ophthalmology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). (2013, background): “7 (bevacizumab) injections per year in the initial years of exudation.(9) In the SEVEN-UP study, there were better visual outcomes among the patients in the highest quartile of anti-VEGF treatments ( 11 injections since HORIZON exit) who gained a mean 3.”
- Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014, neutral): “It is also important to note that the bevacizumab as-needed group did not meet the noninferiority criteria with an as-needed dosing schedule.(12) Intravitreal aflibercept, a fusion protein of key domains from human VEGF receptors 1 and 2 with the constant region (Fc) of human immunoglobulin G, recen”
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results (2012, methodology): “In May 2011, the authors reported the 1-year results of he Comparison of AMD Treatments Trials (CATT).(4) This andomized clinical trial demonstrated that bevacizumab nd ranibizumab had nearly identical effects on visual acuty and that less than monthly, or as-needed, dosing did not ompromise vision.”